Skip to main content

Table 3 Analysis of cancer specific survival (CSS) in RCC, patients without metastases

From: Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma

  Univariate Analysis Multivariate Analysis
Variable HR 95% CI p HR 95% CI p
Stage II vs. I 4.32 2.13-8.73 < 0.0001 3.11 1.48-6.54 0.003
Stage III vs. I 8.94 5.35-14.93 < 0.0001 4.84 2.66-8.80 < 0.0001
Grading 2 vs. 1 1.42 0.73-2.75 0.302 1.11 0.55-2.23 0.768
Grading 3/4 vs. 1 8.91 4.51-17.59 < 0.0001 2.74 1.26-5.95 0.011
Karnofsky < 80 vs. ≥ 80 3.02 1.66-5.48 0.0003 1.82 0.95-3.51 0.072
Age ≥ 65 years vs. < 65 years 1.50 0.95-2.35 0.081 1.01 0.62-1.65 0.965
Sex (Male vs. Female) 1.16 0.73-1.84 0.527 1.37 0.83-2.24 0.216
Clear cell RCC vs. non clear cell RCC 5.43 1.71-17.24 0.004 2.82 0.87-9.22 0.086
Nuclear EZH2 1-5% vs. 0% 1.16 0.64-2.10 0.615 1.21 0.66-2.21 0.546
Nuclear EZH2 >5-25% vs. 0% 0.57 0.23-1.39 0.215 0.60 0.22-1.59 0.301
Nuclear EZH2 >25-50% vs. 0% 3.44 1.54-7.67 0.003 2.72 1.14-6.50 0.025
Nuclear EZH2 >50% vs. 0% 5.11 1.47-17.76 0.010 2.20 0.28-17.42 0.456